Skip to main content
Premium Trial:

Request an Annual Quote

Argos Soditic Acquires Cisbio Bioassays

NEW YORK (GenomeWeb News) – Private equity group Argos Soditic and management members of Cisbio Bioassays today announced that they have acquired Cisbio Bioassays from IBA for an undisclosed amount.

As a result, Cisbio will operate as an independent company.

Based in Codolet, France, Cisbio provides assays and reagents to researchers in the pharmaceutical, biotechnology, and academic markets, as well as to contract research organizations. Its technology portfolio includes Homogeneous Time Resolved Fluorescence. The company has facilities in Bedford, Mass., and Shanghai, and has 200 employees.

Cisbio said that it generates annual revenues of about €35 million ($47.4 million).

The deal will open up opportunities "for strategic growth and will enable [Cisbio] to strengthen its market positions," the firms said, adding that Argos Soditic will help Cisbio implement its strategic plan of innovation, new product launches, and international development.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.